Apexigen, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Burlingame CA United States (2010)
Status: Acquired by Pyxis (2023)

Organization Overview

First Clinical Trial
2015
NCT02482168
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Apexigen America, Inc. | Apexigen, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Astrocytoma (Phase 1)

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Ependymoma (Phase 1)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Head and Neck Neoplasms (Phase 1)

Lung Neoplasms (Phase 2)

Medulloblastoma (Phase 1)

Melanoma (Phase 2)

Sarcoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 13